

VANGUARD RESEARCH GROUP NEWSLETTER

March 2022

GREETINGS!

Even though 2022 is a couple of months old, we hope your year is off to a great start and want to wish all of you a happy and healthy year.

COVID-19 has impacted all of us in unprecedented ways. As we continue to emerge from this pandemic, we explore new ways of conducting trials, have new projects starting and look forward to meeting you face-to-face again at this year's NATCON in D.C.!

COVID-19 AND FUTURE CLINICAL CARE

The COVID-19 pandemic required the health industry to adjust clinical care and research procedures quickly to adapt to the new challenges. But some changes born out of that necessity are here to stay, even after the pandemic is over. The articles below summarize some major developments and their implications for our work going forward:

[Psychiatry and COVID-19 | Psychiatry and Behavioral Health | JAMA | JAMA Network](#)

[Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care](#)

[Lessons learned from COVID-19: The way we develop new medicines is changing \(phrma.org\)](#)

NATCON 2022

VRG will staff a booth again at the **National Council for Behavioral Health NATCON on April 11-12, 2022!** Make sure to stop by **VRG booth #312** to say hello and grab some goodies!

NEW STUDIES UPDATE

- A STUDY INVOLVING AN FDA-APPROVED MEDICATION + DIGITAL APP FOR ADJUNCTIVE TREATMENT OF MDD.
- A NOVEL PHARMACOLOGICAL TREATMENT FOR ACUTE AGITATION IN SCHIZOPHRENIA / BIPOLAR DISORDER FOR USE IN CRISIS STABILIZATION UNITS / PSYCH ER.
- AN APP TRACKING HEALTH MEASURES TO ADVISE CLINICAL CARE IN MOOD DISORDERS AND PSYCHOSIS.
- TESTING A NEW THERAPY APP PROVIDING TREATMENT FOR MDD

If you are interested in learning more or participating, please email Marta Hauser at mhauser@northwell.edu.

FOLLOW US ON SOCIAL MEDIA



<https://www.linkedin.com/company/vanguardresearchgroup>



<https://twitter.com/VRGResearch>



<https://www.facebook.com/VRGResearch/>